Press release
Chronic Hepatitis B Virus Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma
"Chronic Hepatitis B Virus Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.
The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years.
*
Chronic Hepatitis B Virus companies working in the treatment market are Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others, are developing therapies for the Chronic Hepatitis B Virus treatment
*
Emerging Chronic Hepatitis B Virus therapies in the different phases of clinical trials are- AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFN, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.
*
In June 2025, TherVacB, an innovative therapeutic vaccine for chronic hepatitis B developed by Helmholtz Munich in partnership with the German Center for Infection Research (DZIF), began its first clinical trial in patients. After a successful Phase Ia trial in healthy volunteers, which showed a favorable safety profile and induced the intended immune responses, the study has advanced to a multi-center Phase Ib/IIa trial, with the first patient enrolled in June 2025.
*
In May 2025, interim data from a Phase 2b clinical trial showed that AHB-137, Ausperbio's investigational therapy, safely and effectively suppressed the hepatitis B virus (HBV) in individuals with chronic hepatitis B. These encouraging results, consistent with earlier findings from an ongoing Phase 1/2a trial (NCT06115993), were presented during a poster session at the annual European Association for the Study of the Liver Congress.
*
In May 2025, Vir Biotechnology's combination therapy aimed at a "functional cure" for hepatitis B did not meet efficacy endpoints in a Phase II trial. Data from the 24-week mark of the ongoing MARCH Phase II study (NCT04856085) showed that only 17% (3/18) of patients receiving tobevibart and elebsiran alone, and 21% (3/14) of those receiving the combination with peginterferon, achieved undetectable hepatitis B surface antigen (HBsAg) among patients with baseline HBsAg
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, Qilu Pharma here
News-ID: 4162421 • Views: …
More Releases from ABNewswire
Windy City Chimney Heroes Announces Expanded Service Areas Across the Greater Ch …
Windy City Chimney Heroes, a long-standing chimney company established in 1997, has expanded its service areas across the Greater Chicago region. The company now serves Chicago, Evanston, Oak Park, Naperville, Schaumburg, Cicero, Skokie, Berwyn, and Arlington Heights. Owner Wesley Cook says the expansion will help meet rising demand for reliable chimney repair and inspection services.
Windy City Chimney Heroes, a trusted chimney repair and maintenance provider founded in 1997, has announced…
Injury 2 Wellness Centers Promotes Wellness Care Through Ongoing Chiropractic Su …
As the year draws to a close and many individuals begin setting health goals for the new year, Injury 2 Wellness Centers is encouraging Georgia residents to prioritize wellness care through consistent chiropractic treatment. Far beyond addressing back or neck pain, chiropractic care can serve as a foundation for long-term physical health, improved function, and overall quality of life.
Decatur, GA - December 10, 2025 - As the year draws to…
Avalon Tree Services Reminds Atlanta Homeowners to Prioritize Winter Tree Care f …
As temperatures drop and trees enter their dormant season, Avalon Tree Services is reminding homeowners across Greater Atlanta that winter is one of the most important times to invest in proper tree care. Cold weather, ice accumulation, and seasonal storms can all take a toll on tree health and stability-making preventative maintenance essential for safety and long-term growth.
Atlanta, GA - December 10, 2025 - As temperatures drop and trees enter…
TrueProfit Shares 2026 Guidance for Shopify Startups to Focus on Profit First No …
As Shopify heads into 2026 with millions of active stores worldwide and continued growth in global ecommerce, TrueProfit - a Net Profit Analytics platform for Shopify merchants - is urging new founders to treat profitability as a starting requirement, not an afterthought.
With a low barrier to entry and a mature app ecosystem, Shopify remains one of the easiest ways to launch an online business. But TrueProfit's latest briefing on early-stage…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
